The Experimental Therapeutics and Applied Sciences (ETAS) Program aims to facilitate a seamless transition of scientific discoveries, guiding them from bench side to clinical application across the full spectrum of cancer research at the AHWFBCCC.
The ETAS Program conducts highly innovative and integrated research in cancer therapeutics, bioengineering, biotechnology, tumor markers, and tumor model development to address key issues and unmet needs within the AHWFBCCC catchment area.
Specific Aims
Aim 1: Translate Novel Therapeutic Discovery
Accelerate the development of novel small molecule, biologic, cellular, and immunotherapeutic agents for clinical translation.
Aim 2: Develop Novel Bioengineering and Biotechnology
Leverage innovative imaging, surgical, radiotherapeutic, device and drug-delivery technology to transform cancer care outcomes.
Aim 3: Advance Novel Tumor Markers & Tumor Models
Facilitate the translation of advanced computational, preclinical, and clinical cancer modeling to clinical applications.
